Ark Biopharmaceutical

Monoclonal antibodies
#Ark Biopharmaceutical #Monoclonal antibodies #Phase I trial #Respiratory syncytial virus #Virology

Potential monoclonal antibody to prevent RSV enters human trials

Ark Biopharmaceutical (ArkBio) says it has successfully dosed all participants in a Phase I clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection.  The treatment offers a potential a new option for preventing RSV infection for vulnerable infants susceptible… Read More

#News